First, our finding established that targeting TRIM8 reduces GSC stem cell marker expression and self‐renewal capacity, suggesting that TRIM8 and STAT3 signaling pathways are potential therapeutic targets for GBM. The gene discussed is STAT3; the disease is glioblastoma.